Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: A collaborative study with the French endocrine tumor group

Journal of Clinical Oncology

Volumn 24, Issue 11, 2006, Pages 1705-1711

  Chatal, Jean François ^a   Campion, Loïc ^a   Kraeber Bodéré, Françoise ^a   Bardet, Stephane ^a   Vuillez, Jean Philippe ^a   Charbonnel, Bernard ^a   Rohmer, Vincent ^a   Chang, Chien Hsing ^a   Sharkey, Robert M ^a   Goldenberg, David M ^a   Barbet, Jacques ^a  

^a INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BISPECIFIC ANTIBODY; CALCITONIN; CARCINOEMBRYONIC ANTIBODY; HAPTEN; INDIUM; IODINE 131; MONOCLONAL ANTIBODY; PENTETIC ACID;

ARTICLE; CANCER RISK; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MALE; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; THYROID CARCINOMA; UNSPECIFIED SIDE EFFECT; BLOOD; CLINICAL TRIAL; METHODOLOGY; MORTALITY; PROGNOSIS; SURVIVAL; THYROID TUMOR;

ANTIBODIES, MONOCLONAL; CALCITONIN; HUMANS; INDIUM; PENTETIC ACID; PROGNOSIS; RADIOIMMUNOTHERAPY; SURVIVAL ANALYSIS; THYROID NEOPLASMS;

EID: 33645834287     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.04.4917     Document Type: Article

References (18)

1. Van Heerden JA, Grant CS, Gharib H, et al: Long term course of patients with persistent hypercalcitoninemia after apparent curative primary surgery for medullary thyroid carcinoma. Ann Surg 212:395-400, 1990
2. Saad MF, Fritsche HA, Samaan NA: Diagnostic and prognostic values of carcinoembryonic antigen in medullary carcinoma of the thyroid. J Clin Endocrinol Metab 58:889-894, 1984
3. Barbet J, Campion L, Kraeber-Bodéré F, et al: Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. J Clin Endocrinol Metab 90:6077-6084, 2005
4. Kraeber-Bodéré F, Bardet S, Hoefnagel CA, et al: Radioimmunotherapy in medullary thyroid cancer using bispecific antibody and iodine-131-labeled bivalent hapten: Preliminary results of a phase I/II clinical trial. Clin Cancer Res 5:3190s-3198s, 1999
5. Kraeber-Bodéré F, Faivre-Chauvet A, Ferrer L, et al: Pharmacokinetics and dosimetry studies for optimization of anti-carcinoembryonic antigen x antihapten bispecific antibody-mediated pretargetring of iodine-131-labeled hapten in a phase I radioimmunotherapy trial. Clin Cancer Res 9:3973s-3981s, 2003
6. Le Doussal JM, Chetanneau A, Gruaz-Guyon A, et al: Bispecific monoclonal antibody-mediated targeting of an indium-111-labeled-DTPA dimer to primary colorectal tumors: Pharmacokinetics, biodistribution, scintigraphy and immune response. J Nucl Med 34:1662-1671, 1993
7. Hansen HJ, Sullivan CL, Sharkey RM, Goldenberg DM: HAMA interference with murine monoclonal antibody-based immunoassays. J Clin Immunoassay 16:294-299, 1993
8. Therasse P, Arbuck S, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216, 2000
9. Husband JE, Schwartz LH, Spencer J, et al: Evaluation of the response to treatment of solid tumors: A consensus statement of the international cancer imaging society. Br J Cancer 90:2256-2260, 2004
10. Gronlund B, Hogdall C, Hilden J, et al: Should CA-125 response criteria be preferred to response evaluation criteria in solid tumors (RECIST) for prognostication during second-line chemotherapy of ovarian carcinoma? J Clin Oncol 22:4051-4058, 2004
11. 131I-labetuzumab after salvage resection of colorectal metastases in the liver: Five-year safety and efficacy results. J Clin Oncol 23:6763-6770, 2005
12. Mirallie E, Vuillez JP, Bardet S, et al: High frequency of bone/bone marrow involvement in advanced medullary thyroid cancer. J Clin Endocrinol Metab 90:779-788, 2005
13. Sharkey RM, Goldenberg DM: Perspectives on cancer therapy with radiolabeled monoclonal antibodies. J Nucl Med 46:115s-125s, 2005
14. Sharkey RM, Karacay H, Chang CH, et al: Improved therapy of non-Hodgkin's lymphoma xenografts using radionuclides pretargeted with a new anti-CD20 bispecific antibody. Leukemia 19:1064-1069, 2005
15. Wu LT, Averbuch SD, Ball DW, et al: Treatment of advanced medullary thyroid carcinoma with a combination of cyclophosphamide, vincristine, and dacarbazine. Cancer 73:432-436, 1994
16. Schlumberger M, Abdelmoumene N, Delisle MJ, et al: Treatment of advanced medullary thyroid carcinoma. Br J Cancer 71:363-365, 1995
17. Petursson SR: Metastatic thyroid carcinoma: Complete response to combination chemotherapy with dacarbazine and 5-fluorouracil. Cancer 62:1899-1903, 1988
18. Shimaoka K, Schoenfeld DA, Dewys WD, et al: A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 56:2155-2160, 1985